13 citations
,
April 2024 in “JAAD Case Reports” This review discusses current treatments for discoid lupus erythematosus and highlights anifrolumab as a promising option for difficult cases, but no new clinical results are reported.
3 citations
,
January 2025 in “SAGE Open Medical Case Reports” In this case report, a 48-year-old woman with refractory discoid lupus erythematosus showed significant improvement, including hair regrowth, after treatment with deucravacitinib, suggesting its potential as an effective therapy for this condition.
1 citations
,
July 2025 in “Clinical and Experimental Dermatology” In a case report, complete hair regrowth was observed in a patient with severe alopecia areata after treatment with deucravacitinib, a TYK2 inhibitor, suggesting new therapeutic avenues for alopecia areata despite TYK2 not being traditionally linked to this condition.
1 citations
,
January 2023 in “SAGE open medical case reports” This case study reports the first known instance of successful rapid hair regrowth in a psoriasis patient with alopecia universalis after starting deucravacitinib, suggesting potential for TYK2 inhibitors in managing alopecia areata.
June 2026 in “Drugs in Context” This review highlights that deucravacitinib, a selective TYK2 inhibitor, shows promise as an effective treatment for psoriasis and other inflammatory skin diseases, though real-world evidence beyond psoriasis is still emerging.